Medtronic receives FDA approval for newest cardiac devices

Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators.

Advertisement